A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)

PHASE1/PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

HY004

A single infusion of Autologous 2nd generation CD19/CD22-directed CAR-T cells administered intravenously.

DRUG

Cyclophosphamide

Administered intravenously.

DRUG

Fludarabine Phosphate

Administered intravenously.